Last reviewed · How we verify
BTK inhibitor PCI-32765
BTK inhibitor PCI-32765 is a Small molecule drug developed by Kami Maddocks, MD. It is currently in Phase 1 development. Also known as: Bruton's tyrosine kinase inhibitor PCI-32765, PCI-32765.
At a glance
| Generic name | BTK inhibitor PCI-32765 |
|---|---|
| Also known as | Bruton's tyrosine kinase inhibitor PCI-32765, PCI-32765 |
| Sponsor | Kami Maddocks, MD |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma (PHASE1)
- Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia (PHASE2)
- Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (PHASE3)
- Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma (PHASE2)
- Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (PHASE3)
- Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery (PHASE1)
- Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia (PHASE3)
- Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BTK inhibitor PCI-32765 CI brief — competitive landscape report
- BTK inhibitor PCI-32765 updates RSS · CI watch RSS
- Kami Maddocks, MD portfolio CI
Frequently asked questions about BTK inhibitor PCI-32765
What is BTK inhibitor PCI-32765?
BTK inhibitor PCI-32765 is a Small molecule drug developed by Kami Maddocks, MD.
Who makes BTK inhibitor PCI-32765?
BTK inhibitor PCI-32765 is developed by Kami Maddocks, MD (see full Kami Maddocks, MD pipeline at /company/kami-maddocks-md).
Is BTK inhibitor PCI-32765 also known as anything else?
BTK inhibitor PCI-32765 is also known as Bruton's tyrosine kinase inhibitor PCI-32765, PCI-32765.
What development phase is BTK inhibitor PCI-32765 in?
BTK inhibitor PCI-32765 is in Phase 1.
Related
- Manufacturer: Kami Maddocks, MD — full pipeline
- Also known as: Bruton's tyrosine kinase inhibitor PCI-32765, PCI-32765
- Compare: BTK inhibitor PCI-32765 vs similar drugs
- Pricing: BTK inhibitor PCI-32765 cost, discount & access